How much funding has K36 Therapeutics raised?

K36 Therapeutics has raised $100.0M in total funding, most recently a Series B round.

When was K36 Therapeutics founded?

K36 Therapeutics was founded in 2021.

Where is K36 Therapeutics headquartered?

K36 Therapeutics is headquartered in New York, New York, United States.

What industry is K36 Therapeutics in?

K36 Therapeutics operates in Biotech, Drug Discovery, Healthcare.

How many employees does K36 Therapeutics have?

K36 Therapeutics has 1-10 employees.

K36 Therapeutics

Q: Who are K36 Therapeutics's investors?

K36 Therapeutics's investors include F-Prime Capital, Atlas Venture, Eight Roads Ventures.

Home | K36tx

New York, United States · Founded 2021 · $100.0M raised

Biotech

Drug Discovery

Healthcare

Headquarters: New York, New York
Employees: 1–10
Founded: 2021
Business Model: B2B

Website: k36tx.com
Total Funding: $100.0M
Last Round: $70.0M Series BJun 2023
Rounds: 2

About

K36 Therapeutics is a clinical-stage biotech developing KTX-1001 (gintemetostat), a first-in-class oral, selective NSD2/MMSET inhibitor targeting epigenetic drivers of t(4;14) multiple myeloma. The company's lead program is in Phase 1 clinical development, showing target engagement and early clinical activity in relapsed/refractory patients, with a strategy of epigenetic priming to re-sensitize tumors to existing therapies and overcome adaptive resistance.

Summary

K36 Therapeutics is a Biotech company based in New York, United States, founded in 2021. It has raised $100.0M in total across 2 rounds, most recently a $70.0M Series B round in Jun 2023. Investors include F-Prime Capital, Atlas Venture and Eight Roads Ventures.

LinkedIn X (Twitter)